{
  "title": "Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence",
  "url": "https://openalex.org/W4393853520",
  "year": 2024,
  "authors": [
    {
      "id": "https://openalex.org/A4208315106",
      "name": "Ruth Moulson",
      "affiliations": [
        "University of Toronto"
      ]
    },
    {
      "id": "https://openalex.org/A2764351349",
      "name": "Jennifer Law",
      "affiliations": [
        "Princess Margaret Cancer Centre",
        "University Health Network"
      ]
    },
    {
      "id": "https://openalex.org/A2251667460",
      "name": "Adrian Sacher",
      "affiliations": [
        "University Health Network",
        "Princess Margaret Cancer Centre"
      ]
    },
    {
      "id": "https://openalex.org/A2102949679",
      "name": "Geoffrey Liu",
      "affiliations": [
        "Princess Margaret Cancer Centre",
        "University Health Network"
      ]
    },
    {
      "id": "https://openalex.org/A1909090502",
      "name": "Frances A. Shepherd",
      "affiliations": [
        "University Health Network",
        "Princess Margaret Cancer Centre"
      ]
    },
    {
      "id": "https://openalex.org/A2407245378",
      "name": "Penelope Bradbury",
      "affiliations": [
        "University Health Network",
        "Princess Margaret Cancer Centre"
      ]
    },
    {
      "id": "https://openalex.org/A2143480277",
      "name": "Lawson Eng",
      "affiliations": [
        "Princess Margaret Cancer Centre",
        "University Health Network"
      ]
    },
    {
      "id": "https://openalex.org/A2487291246",
      "name": "Sandra Iczkovitz",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A3011200592",
      "name": "Erica Abbie",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A4303632481",
      "name": "Julia Elia-Pacitti",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A2604066594",
      "name": "Emmanuel M. Ewara",
      "affiliations": []
    },
    {
      "id": "https://openalex.org/A5094354062",
      "name": "Viktoriia Mokriak",
      "affiliations": [
        "University of Toronto"
      ]
    },
    {
      "id": "https://openalex.org/A2108384318",
      "name": "Jessica Weiss",
      "affiliations": [
        "University of Toronto"
      ]
    },
    {
      "id": "https://openalex.org/A2796496974",
      "name": "Christopher Pettengell",
      "affiliations": [
        "University of Toronto"
      ]
    },
    {
      "id": "https://openalex.org/A2128605181",
      "name": "Natasha B. Leighl",
      "affiliations": [
        "University Health Network",
        "Princess Margaret Cancer Centre"
      ]
    }
  ],
  "references": [
    "https://openalex.org/W3048896255",
    "https://openalex.org/W6687102121",
    "https://openalex.org/W1967394241",
    "https://openalex.org/W3155376330",
    "https://openalex.org/W2789986687",
    "https://openalex.org/W3134706444",
    "https://openalex.org/W4210992155",
    "https://openalex.org/W2784538417",
    "https://openalex.org/W2158667695",
    "https://openalex.org/W3136653902",
    "https://openalex.org/W2943567636",
    "https://openalex.org/W2194405749",
    "https://openalex.org/W3031120637",
    "https://openalex.org/W4280533169",
    "https://openalex.org/W2976334328",
    "https://openalex.org/W4311677159",
    "https://openalex.org/W4281747485",
    "https://openalex.org/W3085622155",
    "https://openalex.org/W2274623524",
    "https://openalex.org/W2955091219",
    "https://openalex.org/W4387844767",
    "https://openalex.org/W6838348396",
    "https://openalex.org/W4224299761",
    "https://openalex.org/W2904251400",
    "https://openalex.org/W2947071545",
    "https://openalex.org/W4362471337",
    "https://openalex.org/W2970660638",
    "https://openalex.org/W4294943802",
    "https://openalex.org/W4303629062",
    "https://openalex.org/W4283333321",
    "https://openalex.org/W6847411628",
    "https://openalex.org/W4362585394",
    "https://openalex.org/W4309764573",
    "https://openalex.org/W4280525579",
    "https://openalex.org/W2163351155"
  ],
  "abstract": "Real-world evidence for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) in Canada is limited. This studyâ€™s objective was to use previously validated DARWENTM artificial intelligence (AI) to extract data from electronic heath records of patients with non-squamous NSCLC at University Health Network (UHN) to describe EGFR mutation prevalence, treatment patterns, and outcomes. Of 2154 patients with NSCLC, 613 had advanced disease. Of these, 136 (22%) had common sensitizing EGFR mutations (cEGFRm; ex19del, L858R), 8 (1%) had exon 20 insertions (ex20ins), and 338 (55%) had EGFR wild type. One-year overall survival (OS) (95% CI) for patients with cEGFRm, ex20ins, and EGFR wild type tumours was 88% (83, 94), 100% (100, 100), and 59% (53, 65), respectively. In total, 38% patients with ex20ins received experimental ex20ins targeting treatment as their first-line therapy. A total of 57 patients (36%) with cEGFRm received osimertinib as their first-line treatment, and 61 (39%) received it as their second-line treatment. One-year OS (95% CI) following the discontinuation of osimertinib was 35% (17, 75) post-first-line and 20% (9, 44) post-second-line. In this real-world AI-generated dataset, survival post-osimertinib was poor in patients with cEGFR mutations. Patients with ex20ins in this cohort had improved outcomes, possibly due to ex20ins targeting treatment, highlighting the need for more effective treatments for patients with advanced EGFRm NSCLC.",
  "full_text": null,
  "topic": "Osimertinib",
  "concepts": [
    {
      "name": "Osimertinib",
      "score": 0.8905811905860901
    },
    {
      "name": "Medicine",
      "score": 0.8253436088562012
    },
    {
      "name": "Lung cancer",
      "score": 0.7094071507453918
    },
    {
      "name": "Discontinuation",
      "score": 0.6551205515861511
    },
    {
      "name": "Oncology",
      "score": 0.6472057104110718
    },
    {
      "name": "Internal medicine",
      "score": 0.6142710447311401
    },
    {
      "name": "Epidermal growth factor receptor",
      "score": 0.5738365054130554
    },
    {
      "name": "Cohort",
      "score": 0.48517662286758423
    },
    {
      "name": "Targeted therapy",
      "score": 0.44837790727615356
    },
    {
      "name": "Cancer",
      "score": 0.34629905223846436
    },
    {
      "name": "Erlotinib",
      "score": 0.14775055646896362
    }
  ],
  "institutions": [
    {
      "id": "https://openalex.org/I2802654988",
      "name": "Princess Margaret Cancer Centre",
      "country": "CA"
    },
    {
      "id": "https://openalex.org/I1325899441",
      "name": "University Health Network",
      "country": "CA"
    }
  ],
  "cited_by": 5
}